Related Experiment Video
Updated: Jul 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Alterations of Sexual and Erectile Functions after Brachytherapy for Prostate Cancer Based on Patient-Reported
László Gesztesi1, Zsuzsa S Kocsis2, Kliton Jorgo1,3
1National Institute of Oncology, Centre of Radiotherapy, Budapest, Hungary.
High-dose-rate brachytherapy (HDRBT) offers better sexual function recovery than low-dose-rate brachytherapy (LDRBT) for localized prostate cancer patients. HDRBT showed lasting sexual function improvements in hormone-naive patients, unlike LDRBT.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Brachytherapy is a common treatment for localized prostate cancer.
- Both high-dose-rate brachytherapy (HDRBT) and low-dose-rate brachytherapy (LDRBT) are utilized.
- Sexual side effects significantly impact patient quality of life post-treatment.
Purpose of the Study:
- To compare the side effects of HDRBT versus LDRBT on sexual function and well-being.
- To evaluate patient-reported outcomes in localized prostate cancer treated with HDRBT or LDRBT.
- To assess the impact of hormone therapy status on sexual function outcomes following brachytherapy.
Main Methods:
- Prospective study (PROMOBRA) comparing mono LDR (145 Gy) and mono HDR (19/21 Gy) brachytherapy.
- 123 patients received LDRBT, and 117 patients received HDRBT for localized low-risk/low-intermediate-risk prostate cancer.
- Patient-reported outcome measurement (PROM) questionnaires (EORTC QLQ-PR-25, IIEF, IIEF-5) were administered pre-treatment and at multiple follow-up points up to 2 years.
Main Results:
- In hormone-naive patients, LDRBT led to significant, lasting decreases in erectile function, orgasm, sexual desire, and satisfaction.
- HDRBT in hormone-naive patients resulted in transient decreases in sexual function, with recovery observed.
- Hormone-receiving patients showed better orgasm function and sexual desire with HDRBT compared to LDRBT at multiple time points.
Conclusions:
- Both HDRBT and LDRBT are safe for localized prostate cancer treatment.
- HDRBT demonstrates a more advantageous profile for preserving sexual function in hormone-naive patients compared to LDRBT.
- HDRBT may offer superior sexual function outcomes, particularly in hormone-naive prostate cancer patients.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Menopause
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...

